Friday, 13 Jul 2018

You are here

Precision Genetics Can Predict Methotrexate Non-Responders

Investigators from Glasgow and Oxford have identified changes in genomic architecture, represented by a chromosome conformation signature (CCS), that can predict nonresponse to methotrexate in early rheumatoid arthritis (RA) patients.

Recognizing that studies show 35–59% of RA patients do not achieve clinically meaningful responses after starting MTX, they sought to identify a pattern of genetic changes in 59 early RA patients that would predict poor responses to MTX therapy.

Background research suggests that external (epigenetic) perturbations may lead to changes in 3-dimensional structure and the functional regulation of gene activity. Episwitch was used to identify changes in chromosomal conformation signature between two states (disease vs. non-disease, pre-treatment vs. post-treatment). Their results were developed in one cohort and validated in a separate cohort.

Using patients from an early or undifferentiated RA (SERA) study, they identified a 5-marker CCS that could descriminate MTX responders and non-responders at baseline in a cohort of 59 early RA patients.

This genetic "signature" had a negative predictive value of 90% for MTX response. When tested on an independent validation cohort of 19 early RA patients, the signature similary had a high negative predictive value and a 90% sensitivity for identifying MTX non-responders.

Their CCS consisted of chromosome conformations in the genomic regions of IFNAR1, IL-21R, IL-23, CXCL13 and IL-17A. This CCS signature points to a central role in the IL-17/IL-23 axis, with the two most informative long-range chromatin interactions predicting MTX-NR coming from IL-17A and CXCL13 loci.

The authors note that while there are many well-known predictors of RA disease activty, these do not correlate well with treatment responses.

These data demonstrate the ability to predict, a priori, nonresponse to MTX early in the course of the disease. This and other precision tools are desperately needed and require further study.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Diverse Fate of Seronegative Rheumatoid Arthritis

A Finnish Rheumatology Center followed 435 early, seronegative rheumatoid arthritis (RA) patients for 10-years and found that only 3% became erosive or seropositive RA. They also found that 32% could not be further reclassified, and that the remaining 65% evolve into another diagnosis, led by polymyalgia rheumatica (16%), psoriatic arthritis (11%), spondyloarthritis (9%), and osteoarthritis (10%).  

Does RA Have a Prodrome?

A pattern of increased primary care visits and joint complaints during the 2 years before rheumatoid arthritis (RA) was diagnosed were predictive of the diagnosis, a British case-control study found.

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.

Seronegative and Seropositive Rheumatoids Respond Equally Well

A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR  classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.